113 related articles for article (PubMed ID: 3292082)
1. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system.
Fagnart OC; Sindic CJ; Laterre C
Clin Chem; 1988 Jul; 34(7):1387-91. PubMed ID: 3292082
[TBL] [Abstract][Full Text] [Related]
2. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis.
Hartung HP; Reiners K; Schmidt B; Stoll G; Toyka KV
Ann Neurol; 1991 Jul; 30(1):48-53. PubMed ID: 1929228
[TBL] [Abstract][Full Text] [Related]
3. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
4. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
Jury CS; McAllister EJ; MacKie RM
Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
[TBL] [Abstract][Full Text] [Related]
5. ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients.
Marchi N; Mazzone P; Fazio V; Mekhail T; Masaryk T; Janigro D
Cancer; 2008 Mar; 112(6):1313-24. PubMed ID: 18257091
[TBL] [Abstract][Full Text] [Related]
6. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma.
Alber B; Hein R; Garbe C; Caroli U; Luppa PB
Clin Chem Lab Med; 2005; 43(5):557-63. PubMed ID: 15899680
[TBL] [Abstract][Full Text] [Related]
7. Serum neurone-specific enolase concentrations in patients with neurological disorders.
Cunningham RT; Morrow JI; Johnston CF; Buchanan KD
Clin Chim Acta; 1994 Oct; 230(2):117-24. PubMed ID: 7834863
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of serum S100 in metastatic malignant melanoma.
Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
[TBL] [Abstract][Full Text] [Related]
9. Particle-counting immunoassay of a fetuin-like antigen in serum and cerebrospinal fluid.
Fagnart OC; Cambiaso CL; Sindic CJ; Masson PL
Clin Chem; 1985 Nov; 31(11):1820-3. PubMed ID: 2414036
[TBL] [Abstract][Full Text] [Related]
10. Significant increase in immunosuppressive acidic protein (IAP) in serum of patients with multiple sclerosis and other inflammatory neurological disorders.
Tsukamoto T; Seki H; Takase S; Sekizawa T; Nakamura S
J Neurol Sci; 1986 Oct; 75(3):353-61. PubMed ID: 3772394
[TBL] [Abstract][Full Text] [Related]
11. Neuroimmunological findings in Guillain Barré syndrome, multiple sclerosis, and idiopathic polyneuropathies.
Dorta-Contreras A; Silva-Somoza R
Mol Chem Neuropathol; 1996; 28(1-3):279-84. PubMed ID: 8871970
[TBL] [Abstract][Full Text] [Related]
12. S100 protein serum levels in cutaneous malignant melanoma.
Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
[TBL] [Abstract][Full Text] [Related]
13. The clinical relevance of ferritin concentration in the cerebrospinal fluid.
Sindic CJ; Collet-Cassart D; Cambiaso CL; Masson PL; Laterre EC
J Neurol Neurosurg Psychiatry; 1981 Apr; 44(4):329-33. PubMed ID: 7241160
[TBL] [Abstract][Full Text] [Related]
14. T lymphocytes in peripheral blood from patients with neurological diseases.
Nyland H; Naess A
Acta Neurol Scand; 1978 Nov; 58(5):272-9. PubMed ID: 310624
[TBL] [Abstract][Full Text] [Related]
15. Serum S100--a marker for disease monitoring in metastatic melanoma.
Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
[TBL] [Abstract][Full Text] [Related]
16. [S100 protein in tumours of the central nervous system].
Ortiz-Muñoz B; Menéndez-López A; Yayá-Tur R; Arribas-Alpuente L; Maiquez-Richart J; Bordes-Monmeneu M
Rev Neurol; 2003 Jun 1-15; 36(11):1011-5. PubMed ID: 12808493
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum S100 in metastatic malignant melanoma.
Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
Eur J Cancer; 1995 Jun; 31A(6):924-8. PubMed ID: 7646923
[TBL] [Abstract][Full Text] [Related]
18. [The glio-fibrillar acid protein in blood serum of patients with brain tumors and neurological diseases of non-tumorous etiology].
Lyubimova NV; Timofeiev YS; Sushlinskii NE
Klin Lab Diagn; 2016 Aug; 61(8):466-9. PubMed ID: 30601636
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor alpha (TNF alpha) and neurological diseases. Failure in detecting TNF alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours.
Gallo P; Piccinno MG; Krzalic L; Tavolato B
J Neuroimmunol; 1989 Jun; 23(1):41-4. PubMed ID: 2723041
[TBL] [Abstract][Full Text] [Related]
20. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.
Schultz ES; Diepgen TL; Von Den Driesch P
Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
